Rituximab as a first-line therapy in children with new-onset idiopathic nephrotic syndrome.

ABSTRACT:

Background

Idiopathic nephrotic syndrome (INS) in children, commonly treated with steroids, poses challenges due to associated side effects. Rituximab, known for its efficacy in reducing relapse frequency in difficult-to-treat cases, emerges a potential first-line therapy for pediatric new-onset INS.

Method

This is a single-center, retrospective, observational study to evaluate the efficacy and safety of rituximab as a first-line therapy for pediatric INS. The complete treatment strategy was weekly injections at a dose of 375 mg/m² for four doses. Children with new-onset INS who received rituximab as a first-line monotherapy from 1 January 2022 to 31 December 2023 were included and followed until 31 May 2024.

Results

Seventeen patients (median age at diagno

SUBMITTER: Zhang X 

PROVIDER: S-EPMC11730066 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature